{"id":2954,"date":"2026-09-07T10:38:00","date_gmt":"2026-09-07T14:38:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2954"},"modified":"2026-09-08T20:40:15","modified_gmt":"2026-09-09T00:40:15","slug":"rentosertib-shifts-proteomic-aging-clock-readouts","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2954","title":{"rendered":"Rentosertib Shifts Proteomic Aging-Clock Readouts"},"content":{"rendered":"

Evidence<\/strong> Peer-reviewed article · Published<\/strong> September 7, 2026 · Discovery<\/strong> September 7, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Uncertain<\/p>\n

\"Rentosertib<\/p>\n

Summary<\/h4>\n

A Nature Biotechnology analysis applied six proteomic aging clocks to longitudinal serum samples from 42 participants in rentosertib’s randomized Phase IIa idiopathic pulmonary fibrosis trial. Treated groups generally shifted toward lower predicted biological age versus placebo, with the broadest cross-clock agreement at 30 mg twice daily and the strongest concentration of significant comparisons at Week 4. The peer-reviewed result supports integrating multi-clock proteomics into disease trials, but it does not demonstrate biological-age reversal, longevity benefit or a validated surrogate endpoint. Fibrosis biology, small arm sizes and exploratory statistics materially constrain interpretation.<\/p>\n

What Happened<\/h4>\n

The ancillary cohort comprised 42 Asian participants from a 71-patient, 12-week trial at 21 Chinese sites: placebo and each 30 mg regimen contributed 11 participants, and 60 mg once daily contributed nine. Investigators measured 2,841 serum proteins and applied four chronological-age and two mortality-trained clocks. Twenty-one of 54 arm-time-clock comparisons met the authors’ Q-value threshold below 0.10, mainly at Week 4; 30 mg twice daily produced nine such comparisons.<\/p>\n

The 60 mg once-daily regimen, which had shown the largest FVC increase in the original trial, reduced chronological-clock estimates by 2.71 to 3.46 years at Week 4 but did not significantly move the mortality clocks. Change in FVC explained little of the variation in clock change (median R-squared 0.06). In a separate comparison with 55,319 UK Biobank participants, protein changes under 30 mg twice daily correlated inversely with age-associated trajectories (Spearman r=-0.30, P<0.01); the authors call this indirect computational evidence.<\/p>\n

Deep Analysis<\/h4>\n

Multi-clock convergence detects systemic pharmacology:<\/strong> Agreement across clocks trained on different endpoints, combined with dose-schedule divergence from the FVC pattern, suggests the analysis captured more than random assay variation or lung-function change alone. Enrichment of metabolism, senescence and stress-response pathways supplies a biologically coherent hypothesis. Counterevidence is that all clocks reuse overlapping circulating proteins, so apparent convergence is not six independent replications; FVC is also an incomplete measure of changing IPF disease burden.<\/p>\n

Fibrosis improvement drives an aging-like signature:<\/strong> Key contributors included LTBP2 and other extracellular-matrix or fibrosis proteins, and severe IPF itself shifts mortality-trained age estimates. A short disease trial can therefore make proteomes look younger without altering aging biology. Against this explanation, the 30 mg twice-daily arm had broader clock agreement than the 60 mg once-daily arm with the greatest FVC gain — a dissociation that is suggestive, not causal, given the small, post hoc analysis and differing exposure schedules.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: same-day peer-reviewed analysis; randomized parent trial; longitudinal 2,841-protein data; six clocks; 42-person ancillary cohort. Company and author hypothesis: TNIK inhibition may have geroprotective effects beyond antifibrotic activity. Missing facts: preregistration of the aging analysis, clinically validated aging endpoint, non-IPF replication, active-antifibrotic comparator, long-term outcomes and independent laboratory replication. Upgrade evidence would be prospective, two-sided, multiplicity-controlled validation linked to function or morbidity. Downgrade evidence would be loss of signal under stricter correction or after removing fibrosis-dominant proteins.<\/p>\n

Company and Product Background<\/h4>\n

Insilico Medicine develops drug candidates using computational target discovery and generative chemistry. Rentosertib, formerly ISM001-055, is an oral small-molecule inhibitor of TRAF2- and NCK-interacting kinase (TNIK), a signaling node implicated in fibrotic and inflammatory pathways, developed for idiopathic pulmonary fibrosis, a progressive interstitial lung disease characterized by fibroblast activation, extracellular-matrix deposition and declining lung function.<\/p>\n

In the 71-patient Phase IIa trial, treatment-emergent adverse-event rates were broadly similar across arms. The 60 mg once-daily group had a mean 98.4 mL FVC increase at Week 12 versus a 20.3 mL decline with placebo, but the study was small, short and not powered as a confirmatory efficacy trial. Sixteen participants discontinued; common discontinuation events involved liver toxicity or diarrhea, and three acute IPF exacerbations occurred in the 60 mg group versus one with placebo. These facts prevent the ancillary proteomic signal from implying an established benefit-risk profile.<\/p>\n

InSilens Take<\/h4>\n

The high-value signal is trial methodology, not rejuvenation. Multi-clock proteomics may help characterize systemic pharmacodynamics inside conventional disease programs, and the regimen-FVC dissociation justifies prospective testing. Yet predicted biological age is neither a regulatory surrogate nor a clinical outcome, and the analysis cannot separate aging from fibrosis. Rentosertib should therefore receive no efficacy, safety, commercial-readiness or longevity credit from this paper alone; Phase III IPF outcomes and independent biomarker validation remain the governing evidence.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — an unusually detailed human test of integrating multiple proteomic aging clocks into a randomized drug trial<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nUncertain — directionally favorable but exploratory readouts, not validated as biological-age or clinical-benefit measures<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — peer reviewed, with trial registration and quantitative methods disclosed<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nLow-moderate — small samples, shared protein features, disease confounding and a Q<0.10 threshold limit causal claims<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

A Nature Biotechnology analysis applied six proteomic aging clocks to longitudinal serum samples from 42 participants in rentosertib’s randomized Phase IIa idiopathic pulmonary fibrosis trial. Treated groups generally shifted toward lower predicted biological age…<\/p>\n","protected":false},"author":1,"featured_media":2981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[520,594,597,595,596],"class_list":["post-2954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-idiopathic-pulmonary-fibrosis","tag-insilico-medicine","tag-proteomic-aging-clock","tag-rentosertib","tag-tnik-inhibitor"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2954"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2954\/revisions"}],"predecessor-version":[{"id":2986,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2954\/revisions\/2986"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2981"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}